Viking Therapeutics, Inc. (VKTX) Stock Price & Analysis

Viking Therapeutics, Inc. (VKTX) is trading at USD 26.28, down 2.23% today, as of November 18, 2026 at 20:43 UTC (US market open; quotes may be delayed), according to Nexqual market data.

VKTX last closed at USD 26.28; today's session has ranged USD 26.26–27.36 on volume of 2,134,544 shares. Market capitalization is —, with a 52-week range of USD 23.82–43.1 (NCM). Source: Nexqual, retrieved November 18, 2026 at 20:43 UTC.

What changed for VKTX since Aug 31, 2025

The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).

Also available as compact Markdown for AI agents: nexqual.com/VKTX.md

Key facts (VKTX)

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (VKTX)

USDFY2021FY2022FY2023FY2024FY2025TTM
Revenue$0K$0K$0K$0K$0K$0K
Operating income-$55.7M-$70.4M-$101M-$151M-$393M-$649M
Net income-$55.0M-$68.9M-$85.9M-$110M-$360M-$627M
EPS (diluted)-$0.71-$0.90-$0.91-$1.01-$3.19—
Cash + short-term investments$202M$155M$362M$903M$706M—
Total debt————$0K—

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Sep 30, 2026) (VKTX)

P/B 5.8x · Earnings yield -18.51% · Net cash $709M · EV $2.68B

Insider sales (SEC Form 4, open-market, last ~7 months) (VKTX)

0 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

Trade dateInsiderRoleSharesValue% of holdings sold10b5-1 planInsider type
2026-07-29Lian BrianPresident & CEO148,517$4.9M5.5%NoOpportunistic (traded every year 2023–2025, no repeating month)
2026-07-29Zante GregChief Financial Officer21,217$710K9.1%NoOpportunistic (traded every year 2023–2025, no repeating month)
2026-07-29Mancini MariannaChief Operating Officer18,217$610K4.1%NoOpportunistic (traded every year 2023–2025, no repeating month)

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (VKTX)

Rating changes, last 120 days:

DateFirmActionRatingPrice target
2026-10-31Canaccord GenuityTarget raisedBuy$106 → $118
2026-10-20Canaccord GenuityTarget loweredBuy$114 → $106
2026-10-15UBSInitiatedBuy$94
2026-10-07Truist SecuritiesTarget loweredBuy$87 → $85
2026-09-23Truist SecuritiesTarget raisedBuy$83 → $87
2026-08-11JP MorganTarget loweredOverweight$75 → $65
2026-07-30Canaccord GenuityTarget raisedBuy$107 → $114

Total return (dividends reinvested) (VKTX)

1Y (from 2025-11-18)5Y (from 2021-11-15)
Total return-30.4%+366.0%
S&P 500 (SPY)+11.9%+66.7%
Per year-30.4%+36.0%
Volatility (annualized)67.2%91.7%
Max drawdown-42.5% (Jul 2026→Oct 2026)-73.9% (Feb 2024→Apr 2025)

Dividends (VKTX)

VKTX paid no cash dividend in the last five years.

Short interest (VKTX)

24,163,022 shares sold short, 19.93% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 25,921,759 shares (-6.8%). Days to cover: 4.5 (short shares ÷ average daily volume).

VKTX earnings history and stock reaction

Results filedQuarterEPSConsensusSurpriseStock reaction
Oct 28, 2026Quarter ended Sep 30, 2026−$1.55−$1.06Miss −46.2%+7.9%
Jul 29, 2026Quarter ended Jun 30, 2026−$1.10−$1.21Beat +9.1%-2.2%
Apr 29, 2026Quarter ended Mar 31, 2026−$1.37−$0.91Miss −50.5%-3.7%
Feb 11, 2026Quarter ended Dec 31, 2025−$1.38−$0.90Miss −53.3%+6.1%
Oct 22, 2025————+2.9%
Jul 23, 2025————+4.4%
Apr 23, 2025————+0.7%
Feb 5, 2025————-2.8%

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

VKTX recent SEC filings (last 120 days)

FiledFormWhat it says
Nov 5, 2026Schedule 13G/AFMR LLC, Abigail P. Johnson: 7.7% of shares, passive 5%+ holder (amended)
Oct 29, 202610-QQuarterly report · period ended Sep 30, 2026
Oct 28, 20268-KQuarterly results
Sep 28, 20268-KEntered a material agreement; New debt or off-balance-sheet obligation
“Equity Offering On September 23, 2026, Viking Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Equity Underwriting Agreement") with Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC (the "Equity Representatives"), as representatives of the several underwriters named therein (the "Equity Underwriters"), to issue and sell (the "Equity Offering") 7,857,143 shares of the Company's common stock, par value $0.00001 per share ("Common Stock"), at a public offering price of $35.00 per…”
Sep 22, 20268-KOther material event
“On September 22, 2026, Viking Therapeutics, Inc. issued a press release announcing top-line results from its maintenance study of GLP-1/GIP agonist VK2735. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.”
Jul 29, 202610-QQuarterly report · period ended Jun 30, 2026
Jul 29, 20268-KQuarterly results

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

VKTX suppliers, customers and competitors (named in its 10-K)

RelationshipCompanySentence in the filing
PartnerLIGAND PHARMACEUTICALS INC (LGND)“We obtained exclusive worldwide rights to VK2809, VK0214 and VK5211 and certain other assets pursuant to an exclusive license agreement with Ligand Pharmaceuticals Incorporated, or Ligand.”
CompetitorNovo Nordisk (NVO)“VK2735, if approved, will compete against therapies that are already approved and marketed for obesity, including Semaglutide (Wegovy®) and liraglutide (Saxenda®) from Novo Nordisk A/S, and tirzepatide (Zepbound®) from Eli Lilly and Company.”
CompetitorEli Lilly (LLY)“VK2735, if approved, will compete against therapies that are already approved and marketed for obesity, including Semaglutide (Wegovy®) and liraglutide (Saxenda®) from Novo Nordisk A/S, and tirzepatide (Zepbound®) from Eli Lilly and Company.”

Quoted from the company's 10-K filed Feb 11, 2026.

VKTX company outlook (results filed Oct 28, 2026)

Quoted word-for-word from the SEC 8-K results press release.

VKTX analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter (ends Dec 2026)$-1.35$-1.10−$0.25$018
Next quarter (ends Mar 2027)$-1.36$-1.05−$0.31$07
Current fiscal year (ends Dec 2026)$-5.31$-4.61−$0.71$018
Next fiscal year (ends Dec 2027)$-5.21$-4.32−$0.89$018

VKTX options: expected move

ExpirationDaysATM implied volatilityExpected move
Nov 20, 20262123.5%±7.4%
Nov 27, 2026957.9%±7.9%
Dec 4, 20261688.4%±14.9%
Dec 11, 20262382.9%±16.7%
Dec 18, 20263064.0%±15.1%
Dec 24, 20263645.1%±11.4%
Dec 31, 20264356.5%±15.6%
Jan 15, 20275864.3%±20.8%

30-day implied volatility 65.2% vs 74.9% realized over the last 30 trading days. Put/call ratio (volume) 0.68. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of November 18, 2026 at 20:43 UTC)

PriceUSD 26.28
Change▼ 2.23% (down)
Previous CloseUSD 26.28
OpenUSD 26.28
Day RangeUSD 26.26 – 27.36
52-Week RangeUSD 23.82 – 43.1
Volume2,134,544 shares
Market Cap—
ExchangeNCM

Technical Analysis (VKTX)

Nexqual's technical model rates VKTX "SELL" based on 1 bullish and 5 bearish signals across 129 daily candles, as of November 18, 2026 at 20:43 UTC.

Overall SignalSELL
RSI (14)44.49 (neutral)
vs SMA50Below (USD 28.9)
MACD-0.27 (negative)

Earnings (VKTX)

Next Earnings Date2026-10-28
EPS EstimateUSD -1.35
Revenue Estimate$0

Recent Earnings History

QuarterActual vs Estimate
2026-09-30USD -1.55 vs est -1.06 ▼ miss
2026-06-30USD -1.1 vs est -1.21 ▲ beat
2026-03-31USD -1.37 vs est -0.91 ▼ miss
2025-12-31USD -1.38 vs est -0.9 ▼ miss

Source: Nexqual, November 18, 2026 at 20:43 UTC.

Financials & Fundamentals (VKTX)

Gross Margin+0.00%
Operating Margin+0.00%
Profit Margin+0.00%
ROE-96.37%
Debt / Equity0.43
Current Ratio7.27
Total Cash$959.81M
Total Debt$254.69M

Source: Nexqual, November 18, 2026 at 20:43 UTC.

Financial Health Score (VKTX)

Nexqual rates Viking Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of November 18, 2026 at 20:43 UTC.

GrowthMixed — No data
ProfitabilityWeak — Pre-revenue or very early stage
Balance SheetStrong — $960M cash and investments vs $251M debt (Sep 2026, SEC), net cash
Cash FlowWeak — Operating cash flow -$279M (FY ended Dec 2025, 10-K)
EfficiencyCritical — ROE -107%, ROA -64.2% (last 4 quarters, SEC)

Ownership (VKTX)

Insider Ownership+2.83%
Institutional Ownership+64.06%
Shares Outstanding127.52M
Float124.60M
Short % of Float+19.93%

Source: Nexqual, November 18, 2026 at 20:43 UTC.

From Viking Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-11)

Partnerships

Legal & Regulatory Risks (Item 1A, quoted)

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
MDGLMadrigal Pharmaceuticals, Inc.USD 397.1▼ 5.9%
SMMTSummit Therapeutics Inc.USD 10.53▼ 1.36%
TGTXTG Therapeutics, Inc.USD 66.18▲ 5.53%
KODKodiak Sciences IncUSD 98.14▲ 1.38%
BLTEBelite Bio, IncUSD 157.14▼ 0.37%
ORKAOruka Therapeutics, Inc.USD 95.92▼ 0.42%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:43 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt